臨床泌尿器科72巻11号

2018年10月発行

特集 泌尿器科医のためのゲノム腫瘍学入門─時代に取り残されるな

遺伝性腎癌症候群

著者： 蓮見壽史¹ 矢尾正祐¹

所属機関： ¹横浜市立大学大学院医学研究科泌尿器科学

ページ範囲：P.892 - P.901

▶ポイント

・遺伝性腎癌症候群の家系解析などから，10種類以上の腎癌関連遺伝子と，個々の遺伝子変異から起こる遺伝性腎癌が報告されている．

・すべての腎癌関連遺伝子は代謝やクロマチン制御に関わる遺伝子であり，腎癌は代謝とエピゲノムの破綻から発生することが示唆される．

・おのおのの遺伝性腎癌の発生機序の解明は，新規腎癌治療薬開発に重要な役割を果たしている．

参考文献

1） Latif F, Tory K, Gnarra J, et al : Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260 : 1317─1320, 1993

2） Yao M, Latif F, Orcutt ML, et al : von Hippel-Lindau disease : identification of deletion mutations by pulsed-field gel electrophoresis. Hum Genet 92 : 605─614, 1993

3） Yao M, Yoshida M, Kishida T, et al : VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst 94 : 1569─1575, 2002

4） Maxwell PH, Wiesener MS, Chang GW, et al : The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399 : 271─275, 1999

5） Hasumi H and Yao M : Hereditary kidney cancer syndromes : Genetic disorders driven by alterations in metabolism and epigenome regulation. Cancer Sci 109 : 581─586, 2018

6） Cancer Genome Atlas Research Network : Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499 : 43─49, 2013

7） Sato Y, Yoshizato T, Shiraishi Y, et al : Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet 45 : 860─867, 2013

8） Kondo K, Klco J, Nakamura E, et al : Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1 : 237─246, 2002

9） Zhang J, Wu T, Simon J, et al : VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. Science 361 : 290─295, 2018

10） Manalo DJ, Rowan A, Lavoie T, et al : Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood 105 : 659─669, 2005

11） Ricketts CJ, Crooks DR and Linehan WM : Targeting HIF2α in Clear-Cell Renal Cell Carcinoma. Cancer Cell 30 : 515─517, 2016

12） Nickerson ML, Warren MB, Toro JR, et al : Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome. Cancer Cell 2 : 157─164, 2002

13） Hasumi H, Baba M, Hasumi Y, et al : Birt-Hogg-Dubé syndrome : Clinical and molecular aspects of recently identified kidney cancer syndrome. Int J Urol 23 : 204─210, 2016

14） Hasumi H, Hasumi Y, Baba M, et al : H255Y and K508R missense mutations in tumour suppressor folliculin（FLCN） promote kidney cell proliferation. Hum Mol Genet 26 : 354─366, 2017

15） Hasumi Y, Baba M, Ajima R, et al : Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2. Proc Natl Acad Sci USA 106 : 18722─18727, 2009

16） Furuya M, Yao M, Tanaka R, et al : Genetic, epidemiologic and clinicopathologic studies of Japanese Asian patients with Birt-Hogg-Dubé syndrome. Clin Genet 90 : 403─412, 2016

17） Hasumi H, Furuya M, Tatsuno K, et al : BHD-associated kidney cancer exhibits unique molecular characteristics and a wide variety of variants in chromatin remodeling genes. Hum Mol Genet, 2018 ［Epub ahead of print］

18） Laviolette LA, Mermoud J, Calvo IA, et al : Negative regulation of EGFR signalling by the human folliculin tumour suppressor protein. Nat Commun 8 : 15866, 2017

19） Zheng J, Duan B, Sun S, et al : Folliculin Interacts with Rab35 to Regulate EGF-Induced EGFR Degradation. Front Pharmacol 8 : 688, 2017

20） Tsun ZY, Bar-Peled L, Chantranupong L, et al : The folliculin tumor suppressor is a GAP for the RagC/D GTPases that signal amino acid levels to mTORC1. Mol Cell 52 : 495─505, 2013

21） Petit CS, Roczniak-Ferguson A and Ferguson SM : Recruitment of folliculin to lysosomes supports the amino acid-dependent activation of Rag GTPases. J Cell Biol 202 : 1107─1122, 2013

22） Hasumi H, Baba M, Hasumi Y, et al : Regulation of mitochondrial oxidative metabolism by tumor suppressor FLCN. J Natl Cancer Inst 104 : 1750─1764, 2012

23） Hasumi Y, Baba M, Hasumi H, et al : Folliculin（Flcn） inactivation leads to murine cardiac hypertrophy through mTORC1 deregulation. Hum Mol Genet 23 : 5706─5719, 2014

24） Baba M, Endoh M, Ma W, et al : Folliculin Regulates Osteoclastogenesis Through Metabolic Regulation. J Bone Miner Res, 2018 ［Epub ahead of print］

25） Hong SB, Oh H, Valera VA, et al : Inactivation of the FLCN tumor suppressor gene induces TFE3 transcriptional activity by increasing its nuclear localization. PLoS One 5 : e15793, 2010

26） Baba M, Hong SB, Sharma N, et al : Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc Natl Acad Sci USA 103 : 15552─15557, 2006

27） Baba M, Keller JR, Sun HW, et al : The folliculin-FNIP1 pathway deleted in human Birt-Hogg-Dubé syndrome is required for murine B-cell development. Blood 120 : 1254─1261, 2012

28） Baba M, Toyama H, Sun L, et al : Loss of Folliculin Disrupts Hematopoietic Stem Cell Quiescence and Homeostasis Resulting in Bone Marrow Failure. Stem Cells 34 : 1068─1082, 2016

29） Baba M, Furihata M, Hong SB, et al : Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model : Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys. J Natl Cancer Inst 100 : 140─154, 2008

30） Hasumi H, Baba M, Hasumi Y, et al : Folliculin-interacting proteins Fnip1 and Fnip2 play critical roles in kidney tumor suppression in cooperation with Flcn. Proc Natl Acad Sci USA 112 : E1624─1631, 2015

31） Hasumi H, Baba M, Hong SB, et al : Identification and characterization of a novel folliculin-interacting protein FNIP2. Gene 415 : 60─67, 2008

32） Tomlinson IP, Alam NA, Rowan AJ, et al : Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 30 : 406─410, 2002

33） Isaacs JS, Jung YJ, Mole DR, et al : HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer : novel role of fumarate in regulation of HIF stability. Cancer Cell 8 : 143─153, 2005

34） Xiao M, Yang H, Xu W, et al : Inhibition of α-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes Dev 26 : 1326─1338, 2012

35） Cancer Genome Atlas Research Network, et al : Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med 374 : 135─145, 2016

36） Sulkowski PL, Sundaram RK, Oeck S, et al : Krebs-cycle-deficient hereditary cancer syndromes are defined by defects in homologous-recombination DNA repair. Nat Genet 50 : 1086─1092, 2018

37） Adam J, Hatipoglu E, O'Flaherty L, et al : Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway : roles for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell 20 : 524─537, 2011

38） Gill AJ, Pachter NS, Clarkson A, et al : Renal tumors and hereditary pheochromocytoma-paraganglioma syndrome type 4. N Engl J Med 364 : 885─886, 2011

39） Letouzé E, Martinelli C, Loriot C, et al : SDH mutations establish a hypermethylator phenotype in paraganglioma. Cancer Cell 23 : 739─752, 2013

40） Schmidt L, Duh FM, Chen F, et al : Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16 : 68─73, 1997

41） Haas NB and Nathanson KL : Hereditary kidney cancer syndromes. Adv Chronic Kidney Dis 21 : 81─90, 2014

42） Nakaigawa N, Yao M, Baba M, et al : Inactivation of von Hippel-Lindau gene induces constitutive phosphorylation of MET protein in clear cell renal carcinoma. Cancer Res 66 : 3699─3705, 2006

43） Gilbert JA : Savolitinib for MET-driven papillary renal cell carcinoma. Lancet Oncol 18 : e440, 2017

44） Choueiri TK, Escudier B, Powles T, et al : Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med 373 : 1814─1823, 2015

45） Xie Z, Lee YH, Boeke M, et al : MET Inhibition in Clear Cell Renal Cell Carcinoma. J Cancer 7 : 1205─1214, 2016

46） Tyburczy ME, Jozwiak S, Malinowska IA, et al : A shower of second hit events as the cause of multifocal renal cell carcinoma in tuberous sclerosis complex. Hum Mol Genet 24 : 1836─1842, 2015

47） Inoki K, Zhu T and Guan KL : TSC2 mediates cellular energy response to control cell growth and survival. Cell 115 : 577─590, 2003

48） Shuch B, Ricketts CJ, Vocke CD, et al : Germline PTEN mutation Cowden syndrome : an underappreciated form of hereditary kidney cancer. J Urol 190 : 1990─1998, 2013

49） Davis CF, Ricketts CJ, Wang M, et al : The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell 26 : 319─330, 2014

50） Farley MN, Schmidt LS, Mester JL, et al : A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma. Mol Cancer Res 11 : 1061─1071, 2013

51） Carbone M, Yang H, Pass HI, et al : BAP1 and cancer. Nat Rev Cancer 13 : 153─159, 2013

52） Liao L, Testa JR and Yang H : The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer. Cancer Genet 208 : 206─214, 2015

53） Dey A, Seshasayee D, Noubade R, et al : Loss of the tumor suppressor BAP1 causes myeloid transformation. Science 337 : 1541─1546, 2012

54） Landreville S, Agapova OA, Matatall KA, et al : Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. Clin Cancer Res 18 : 408─416, 2012

55） Benusiglio PR, Couvé S, Gilbert-Dussardier B, et al : A germline mutation in PBRM1 predisposes to renal cell carcinoma. J Med Genet 52 : 426─430, 2015

56） Nargund AM, Pham CG, Dong Y, et al : The SWI/SNF Protein PBRM1 Restrains VHL-Loss-Driven Clear Cell Renal Cell Carcinoma. Cell Rep 18 : 2893─2906, 2017

57） Wang SS, Gu YF, Wolff N, et al : Bap1 is essential for kidney function and cooperates with Vhl in renal tumorigenesis. Proc Natl Acad Sci USA 111 : 16538─16543, 2014

58） Foster RE, Abdulrahman M, Morris MR, et al : Characterization of a 3;6 translocation associated with renal cell carcinoma. Genes Chromosomes Cancer 46 : 311─317, 2007

59） Jafri M, Wake NC, Ascher DB, et al : Germline Mutations in the CDKN2B Tumor Suppressor Gene Predispose to Renal Cell Carcinoma. Cancer Discov 5 : 723─729, 2015

60） Carlo MI, Mukherjee S, Mandelker D, et al : Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma. JAMA Oncol, 2018 ［Epub ahead of print］

61） Whitworth J, Skytte AB, Sunde L, et al : Multilocus Inherited Neoplasia Alleles Syndrome : A Case Series and Review. JAMA Oncol 2 : 373─379, 2016